Integrins are cell adhesion receptors predominantly important during normal and tumor angiogenesis. A sequence present on several extracellular matrix proteins composed of Arg-Gly-Asp (RGD) has attracted attention due to its role in cell adhesion mediated by integrins. The development of ligands that can bind to integrins involved in tumor angiogenesis and brake disease progression has resulted in new investigational drug entities reaching the clinical trial phase in humans. The use of integrin-specific ligands can be useful for the vascularization of regenerative medicine constructs, which remains a major limitation for translation into clinical practice. In order to enhance vascularization, immobilization of integrin-specific RGD peptidomimetics within constructs is a recommended approach, due to their high specificity and selectivity towards certain desired integrins. This review endeavours to address the potential of peptidomimetic-coated biomaterials as vascular network promoters for regenerative medicine purposes. Clinical studies involving molecules tracking active integrins in cancer angiogenesis and reasons for their failure are also addressed.

整联蛋白是正常和肿瘤血管生成过程中最重要的细胞粘附受体。存在于由Arg-Gly-Asp（RGD）组成的几种细胞外基质蛋白上的序列由于其在整联蛋白介导的细胞粘附中的作用而引起人们的关注。可以与参与肿瘤血管生成和制动疾病进展的整合素结合的配体的发展已导致新的研究药物实体进入人体临床试验阶段。整联蛋白特异性配体的使用可用于再生药物构建体的血管形成，这仍然是翻译成临床实践的主要限制。为了增强血管生成，建议将整合素特异性RGD拟肽固定在构建体中，由于它们对某些所需整联蛋白的高度特异性和选择性。这项审查致力于解决肽模拟物涂层的生物材料作为再生医学目的的血管网络促进剂的潜力。还研究了涉及在肿瘤血管生成中追踪活性整合素的分子及其失败原因的临床研究。